Milestone Asset Management LLC Buys New Position in Johnson & Johnson (NYSE:JNJ)

Milestone Asset Management LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,539 shares of the company’s stock, valued at approximately $512,000.

A number of other institutional investors have also modified their holdings of the company. Powers Advisory Group LLC boosted its holdings in Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after purchasing an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC raised its position in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after purchasing an additional 63 shares in the last quarter. Knuff & Co LLC boosted its stake in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after buying an additional 64 shares during the last quarter. Perkins Coie Trust Co grew its position in shares of Johnson & Johnson by 1.8% during the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock worth $600,000 after buying an additional 65 shares in the last quarter. Finally, Vertex Planning Partners LLC increased its stake in shares of Johnson & Johnson by 1.3% in the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after buying an additional 65 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research analyst reports. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners decreased their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Barclays upped their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Bank of America dropped their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $152.09 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm has a market capitalization of $366.17 billion, a PE ratio of 22.87, a P/E/G ratio of 2.43 and a beta of 0.51. The firm has a 50-day moving average price of $147.61 and a 200 day moving average price of $156.09. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $2.29 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.26%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.